Abstract
Purpose. To evaluate the magnitude of the solubility advantage foramorphous pharmaceutical materials when compared to their crystallinecounterparts.Methods. The thermal properties of several drugs in their amorphousand crystalline states were determined using differential scanningcalorimetry. From these properties the solubility advantage for theamorphous form was predicted as a function of temperature using a simplethermodynamic analysis. These predictions were compared to theresults of experimental measurements of the aqueous solubilities of theamorphous and crystalline forms of the drugs at several temperatures.Results. By treating each amorphous drug as either an equilibriumsupercooled liquid or a pseudo-equilibrium glass, the solubilityadvantage compared to the most stable crystalline form was predicted to bebetween 10 and 1600 fold. The measured solubility advantage wasusually considerably less than this, and for one compound studied indetail its temperature dependence was also less than predicted. It wascalculated that even for partially amorphous materials the apparentsolubility enhancement (theoretical or measured) is likely to influencein-vitro and in-vivo dissolution behavior.Conclusions. Amorphous pharmaceuticals are markedly more solublethan their crystalline counterparts, however, their experimental solubility advantage is typically less than that predicted from simplethermodynamic considerations. This appears to be the result of difficulties indetermining the solubility of amorphous materials under trueequilibrium conditions. Simple thermodynamic predictions can provide a useful indication of the theoretical maximum solubility advantage foramorphous pharmaceuticals, which directly reflects the driving forcefor their initial dissolution.
Similar content being viewed by others
REFERENCES
B. C. Hancock and G. Zografi. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86:1–12 (1997).
D. J. W. Grant and T. Higuchi, Solubility behavior of organic compounds, 1st ed., John Wiley & Sons, New York, 1990.
R. J. Behme and D. Brooke. Heat of fusion measurement of a low melting polymorph of carbamezapine that undergoes multiple-phase changes during differential scanning calorimetry analysis. J. Pharm. Sci. 80:986–990 (1991).
A. J. Aguiar, J. Krc, A. W. Kinkel, and J. C. Samyn. Effect of polymorphism on the absorption of chloramphenicol from chloramphenicol palmitate. J. Pharm. Sci. 57:847–853 (1967).
A. J. Aguiar and J. E. Zelmer. Dissolution behaviour of polymorphs of chloramphenicol palmitate and mefenamic acid. J. Pharm. Sci. 58:983–987 (1969).
H. Imaizumi. Stability and several physical properties of amorphous and crystalline forms of indomethacin. Chem. Pharm. Bull. 28:2565-2569 (1980).
H. Egawa, S. Maeda, E. Yonemochi, T. Oguchi, K. Yamamoto, and Y. Nakai. Solubility parameter and dissolution behaviour of cefalexin powders with different crystallinity. Chem. Pharm. Bull. 40:819–820 (1992).
S. Miyazaki, R. Hori, and T. Arita. Physico-chemical and gastrointestinal absorption of some solid phases of tetracycline. Yakugaku Zasshi 95:629–633 (1975).
T. Sato, A. Okada, K. Sekiguchi, and Y. Tsuda. Difference in physico-pharmaceutical properties between crystalline and non-crystalline 9,3”-diacetylmidecamycin. Chem. Pharm. Bull. 29:2675–2682 (1981).
J. D. Mullins and T. J. Macek. Some pharmaceutical properties of novobiocin. J. Pharm. Sci. 49:245–248 (1960).
E. Fukuoka, M. Makita, and S. Yamamura. Glassy state of pharmaceuticals. 2: Bioinequivalence of glassy and crystalline indomethacin. Chem. Pharm. Bull. 35:2943–2948 (1987).
G. S. Parks, H. M. Huffman, and F. R. Cattor. Studies on glass. II: The transition between the glassy and liquid states in the case of glucose. J. Phys. Chem. 32:1366–1379 (1928).
G. S. Parks, L. J. Snyder, and F. R. Cattoir. Studies on glass. XI: Some thermodynamic relations of glassy and alpha-crystalline glucose. J. Chem. Phys. 2:595–598 (1934).
W. I. Higuchi, P. K. Lau, T. Higuchi, and J. W. Shell. Polymorphism and drug availability. Solubility relationships in the methylprednisolone system. J. Pharm. Sci. 52:150–153 (1963).
S. H. Neau and G. L. Flynn. Solid and liquid heat capacities of n-alkyl para-aminobenzoates near the melting point. Pharm. Res. 7:1157–1162 (1990).
S. H. Neau, S. V. Bhandarkar, and E. W. Hellmuth. Differential molar heat capacities to test ideal solubility estimations. Pharm. Res. 14:601–605 (1997).
S. H. Neau, G. L. Flynn, and S. H. Yalkowsky. The influence of heat capacity assumptions on the estimation of solubility parameters from solubility data. Int. J. Pharm. 49:223–229 (1989).
S. L. Shamblin, X. Tang, L. Chang, B. C. Hancock, and M. J. Pikal. Characterization of the time scales of molecular motion in pharmaceutically important glasses. J. Phys. Chem. B. 103:4113–4121 (1999).
M. O'Brien, J. McCauley, and E. Cohen. Indomethacin. In H. G. Brittain (ed), Analytical Profiles of Drug Substances, Volume 13, Academic Press, London, UK, 1984, pp. 211–238.
M. Yoshioka, B. C. Hancock, and G. Zografi. Crystallisation of indomethacin from the amorphous state below and above its glass transition temperature. J. Pharm. Sci. 83:1700–1705 (1994).
W. C. Stagner and J. K. Guillory. Physical characterization of solid iopanoic acid forms. J. Pharm. Sci. 68:1005–1009 (1979).
V. Andronis, M. Yoshioka, and G. Zografi. Effects of sorbed water on the crystallization of indomethacin from the amorphous state. J. Pharm. Sci. 86:346–351 (1997).
O. I. Corrigan, E. M. Holohan, and K. Sabra. Amorphous forms of thiazide diuretics prepared by spray-drying. Int. J. Pharm. 18:195–200 (1984).
N. Kaneniwa, M. Otsuka, and T. Hayashi. Physicochemical characterization of indomethacin polymorphs and the transformation kinetics in ethanol. Chem. Pharm. Bull. 33:3447–3455 (1985).
M. Kanke and K. Sekiguchi. Dissolution behaviour of solid drugs. 2: Determination of the transition temperature of sulfathiazole polymorphs by measuring the initial dissolution rate. Chem. Pharm. Bull. 21:878–884 (1973).
A. Burger. Zur Polymorphie oraler Antidiabetika. Scientia Pharmaceutica 43:161–168 (1975).
H.G. Brittain (ed.), Polymorphism in pharmaceutical solids, Marcel Dekker, New York, USA, 1999.
S. Byrn, R. Pfeiffer, M. Ganey, C. Hoiberg, and G. Poochikian. Pharmaceutical solids: a strategic approach to regulatory considerations. Pharm. Res. 12:945–954 (1995).
A. A. Elamin, C. Ahlneck, G. Alderborn, and C. Nystrom. Increased metastable solubility of milled griseofulvin, depending on the formation of a disordered surface structure. Int. J. Pharm. 111:159–170 (1994).
M. Mosharraf and C. Nystrom. The effect of dry mixing on the apparent solubility of some sparingly soluble drugs. PharmSci 1:S268 (1998).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hancock, B.C., Parks, M. What is the True Solubility Advantage for Amorphous Pharmaceuticals?. Pharm Res 17, 397–404 (2000). https://doi.org/10.1023/A:1007516718048
Issue Date:
DOI: https://doi.org/10.1023/A:1007516718048